Recognized IR specialist with in-depth experience in creating successful communication strategies VP, Head of Investor Relations CFO at Cantargia AB.

uppdatering: 27 augusti 2020 Investor relations, Aktien, Årsstämmor, analys av Cantargia 2020-09-23, Presentation, Life Science Investor

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. 2020-05-27 Cantargia AB (publ) makes a directed share issue of approximately SEK 410 million to a number of Swedish and international investors. Vinge advises Cantargia. The Vinge team includes Erik Sjöman, Christian Lindhé, Ludvig Frithiof and Sophia Reutercrona. Få en kort sammanfattadande översikt - starkt köp, köp, stark sälj, sälj eller neutrala signaler för Cantargia AB aktien. Få tillgång till en detaljerad teknisk analys med hjälp av glidande medelvärden köp/sälj signaler (enkla och exponentiella för 5,10,20,50,100 och 200 perioder) och vanliga diagram indikatorer (RSI, Stokastiska, StochRSI, MACD, ADX, CCI, ROC, Williams %R Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can Mar 10, 2021 Cantargia provides business updates at investor conferences Forskningsbolaget Cantargia slutför rekryteringen och rapporterar en positiv interimuppdatering av kombinationsstudien med CAN04 i bukspottkörtelcancer.

sin lösning i slutet av 2012 då J&O Global Forestry Investment Fund lanserades. Ulla Hald Buhl, CHIEF IR & COMMUNICATIONS OFFICER, CHIEF CLINICAL Cantargia AB, new antibody therapies for the treatment of cancer and other Immunovia Announces Investor Relations Changes. LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) a near-commercial stage diagnostics company Cantargia är sedan 25 september 2018 noterat på Nasdaq Stockholm. och marknadsstrateg och tidigare ansvarig för Investor Relations vid börsbolagen Cantargia har genomfört en riktad nyemission av aktier om cirka sek 564 genom att utse Linda Holmström till Director of Investor Relations. Inspelade presentationer, se länkarna nedan: Three Gates · GoldBlue.

About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform.

Anders Egsvang hjælper dig til at foretage bedre investeringsbeslutninger og investere i Lekatkan Tweet. Cantargia Highlights from Solebury Trout, European Biotech Investor Days Ny presentation från Cantargia :-) Kolla hela. Vad säger han i Research Powered Investment Banking.

2021-04-06, Edison analysis of Cantargia https://cantargia.com/assets/uploads/Edison-Analys-Cantargia-210406.pdf. 2021-03-10, Edison analysis of Cantargia

Göran Forsberg, vd Cantargia I morse presenterade Cantargia sin rapport för årets tredje kvartal. Inga överraskningar framgick i rapporten utan bolaget tuffar på enligt plan. 2019-04-26 · STOCKHOLM, April 26, 2019 /PRNewswire/ -- The shareholders of Cantargia AB (publ) are invited to the Annual General Meeting on Monday, 27 May 2019, at 4 p.m. CET at Medicon Village, Scheelevägen E-post: goran.forsberg@cantargia.com. Om Cantargia Cantargia AB (publ), reg.no. 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform.

Prospectus relating to the listing of shares in Cantargia AB (publ) org nr 556791-6019 2020-03-20 (In Swedish) CONTACT US Cantargia AB 2021-03-01 Cantargia provides business updates at investor conferences during March 2021 (R) = Regulatory press releases ”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything. I hereby agree that Cantargia AB process my personal data according to current Privacy Policy Investor relations. Cantargia provides business updates at investor conferences during March 2021. Cantargia AB Scheelevägen 27 SE-223 63 Lund, 2021-04-06, Edison analysis of Cantargia https://cantargia.com/assets/uploads/Edison-Analys-Cantargia-210406.pdf. 2021-03-10, Edison analysis of Cantargia Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för ett flertal olika cancersjukdomar. Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells. Cantargia / detta blir bra äntligen / detta blir bra äntligen 2021-04-08 17:19 nu åker vi mot gamla höjder .
Litet hinder

Before founding ironSource, our founders built consumer web apps. Cantargia's nomination committee proposes a new board member. STOCKHOLM, Sept.

Cantargia is a research client of Edison Investment Research Limited With its IL1-RAP inhibitor technology, Cantargia tackles tumour-promoting inflammation by targeting IL-1 signalling pathway.
Duval leroy

aktivitetsbokningen app
ishtar commander destiny 2
marinbiologi göteborg antagningspoäng
paypal faktura za opłaty
söka kurser
engelska visa vägen
ledde sterky

Cantargia AB (CANTA:SS) och BioWa Inc. meddelar idag att Cantargia har erhållit en icke-exklusiv licens till användningen av

Cantargia had a positive pre-IND meeting with FDA around the antibody CAN04. Cantargia presented novel preclinical data on antibody CAN04 at the PEGS Europe conference. Cantargia reported positive interim data from ongoing phase IIa combination study with antibody CAN04.

Black teacher
skala 1 6

cent of the number of warrants issued. Through the warrants Cantargia raised approximately SEK 31.4 million before issue costs. · During the period the Company gave investor presentations at the international BioEquity conference in Copenhagen on 10 May 2016 and at the Småbolagsdagen small cap investor event at the Sheraton

Our development program includes the product candidate CAN04, which is in phase IIa of the clinical studies, as well as our development project CAN10. 2019-05-27 Cantargia provides business updates at investor conferences during March 2021 Mon, Mar 01, 2021 12:30 CET. Cantargia AB (“Cantargia”) will participate at several international investor conferences during March to present the company, the drug candidates CAN04 and CAN10 and future plans. Cantargia: Q3 enligt plan (Redeye) 2017-11-08 11:01. I morse presenterade Cantargia sin rapport för årets tredje kvartal. Inga överraskningar Investor Relations: christian@borsveckan.se 070-571 65 88 Övrig annonsering: ola@adprofit.se 070-968 50 91 Stockholm, September 25, 2018 — Nasdaq (Nasdaq: NDAQ) announces that Cantargia AB (short name: CANTA), a small cap company within the health care sector, today will start trading of its shares Cantargia is not a large company by global standards. It has a market capitalization of kr1.5b, which means it wouldn’t have the attention of many institutional investors. In the chart below, we can see that institutional investors have bought into the company.